Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer

Tyrosine kinase inhibitors (TKIs) have shown strong activity against non-small-cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations. However, a fraction of EGFR wild-type (WT) patients may have an improvement in terms of response rate and progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sette, G, Salvati, V, Mottolese, M, Visca, P, Gallo, E, Fecchi, K, Pilozzi, E, Duranti, E, Policicchio, E, Tartaglia, M, Milella, M, De Maria, R, Eramo, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558509/
https://www.ncbi.nlm.nih.gov/pubmed/26247735
http://dx.doi.org/10.1038/cddis.2015.217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558509/
https://www.ncbi.nlm.nih.gov/pubmed/26247735
http://dx.doi.org/10.1038/cddis.2015.217

Ejemplares similares